NJA-002

N/A

Report date: 2024/02/01 17:47:28

Base Information

Drug NameNJA-002
Drug Alias NameNJA-002
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy
Mechanisms of ActionCD8A modulatorsT-cell surface glycoprotein CD8 beta chain modulators
TargetsT-cell surface glycoprotein CD8 beta chainT-cell surface glycoprotein CD8 alpha chain
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesShinobi Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesShinobi Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A